Raymond James & Associates Ardelyx, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Ardelyx, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 21,515 shares of ARDX stock, worth $113,599. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,515
Previous 20,211
6.45%
Holding current value
$113,599
Previous $149,000
0.67%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ARDX
# of Institutions
222Shares Held
167MCall Options Held
517KPut Options Held
1.61M-
Black Rock Inc. New York, NY17.6MShares$92.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$84.6 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X015.1MShares$79.5 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7MShares$61.6 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C311.5MShares$60.5 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $816M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...